HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.

AbstractOBJECTIVE:
The objective of this study was to evaluate patterns of recurrence and prognostic factors as well as the role of adjuvant chemotherapy in stage II-IV ovarian SBT.
METHODS:
We performed a retrospective review of all patients with advanced-stage SBT treated at our institution from 1979 to 2008. Advanced stage was defined as FIGO stage II-IV. Progression-free survival (PFS) was defined as the time of diagnosis to time of recurrence/death or last follow-up. Kaplan-Meier method was used to report the PFS rate.
RESULTS:
A total of 80 stage II-IV patients were identified, of which 15 (19%) were stage II, 63 (79%) were stage III, and 2 (2.5%) were stage IV. The site of metastasis was pelvis in 15 patients (19%), omentum in 29 patients (36%), isolated lymph nodes in 2 patients (2.5%), lung in 1 patient (1%), axilla in 1 patient (1%), and multiple sites in 32 patients (40%). With a median follow-up of 4.8 years, 17 patients (21%) developed recurrent disease. Only patients with metastasis to the omentum or multiple sites developed recurrent disease. Of the 65 stage III/IV patients, 17 patients (26%) received adjuvant chemotherapy following diagnosis. The 3-year progression-free survival (PFS) was 89.9% (95% CI, 77.3-95.7) for patients who did not receive adjuvant chemotherapy compared with 70.6% (95% CI, 43.1-86.6) for patients who received adjuvant chemotherapy.
CONCLUSIONS:
While advanced-stage ovarian SBT generally has a good prognosis, nearly 21% of patients develop recurrent disease with intermediate follow-up. It is unclear from these data if adjuvant chemotherapy influenced PFS.
AuthorsKarin K Shih, Qin C Zhou, Carol Aghajanian, Jae Huh, Robert A Soslow, Jessica C Morgan, Alexia Iasonos, Dennis S Chi, Richard R Barakat, Nadeem R Abu-Rustum
JournalGynecologic oncology (Gynecol Oncol) Vol. 119 Issue 2 Pg. 270-3 (Nov 2010) ISSN: 1095-6859 [Electronic] United States
PMID20719369 (Publication Type: Journal Article)
CopyrightCopyright © 2010 Elsevier Inc. All rights reserved.
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Chemotherapy, Adjuvant
  • Cystadenocarcinoma, Serous (drug therapy, pathology, surgery)
  • Disease-Free Survival
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local (pathology)
  • Neoplasm Staging
  • Ovarian Neoplasms (drug therapy, pathology, surgery)
  • Retrospective Studies
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: